Marshall Wace

Rezolute Inc., established in 2010 and headquartered in Redwood City, California, is a clinical-stage biopharmaceutical company focused on developing therapies for rare and metabolic diseases. The company's primary product candidate, RZ358, is a human monoclonal antibody currently in Phase 2b trials for treating congenital hyperinsulinism, an ultra-rare pediatric genetic disorder. Additionally, Rezolute is advancing RZ402, a small molecule plasma kallikrein inhibitor in preclinical stages for diabetic macular edema treatment. The company aims to improve existing standards of care by applying proprietary formulation and manufacturing capabilities to known molecules.

Attovia Therapeutics is a biotherapeutics pipeline developer focused on immune-mediated illness and oncology. The company uses the nanobody platform to create tiny format binders with low picomolar affinity, increased selectivity, quicker internalization, and rapid tissue penetration, thereby assisting cancer patients' treatment.

Sammaan Capital is a mortgage-focused non-banking financial company based in India, founded in 2000. The company specializes in providing a range of financial services, including home loans, loans for non-resident Indians, and loans against properties, all offered at competitive interest rates. Catering to both salaried and self-employed individuals, Sammaan Capital aims to facilitate quick access to funding for various purposes such as construction, renovation, and the purchase of residential properties, including apartments, flats, and bungalows. Additionally, the company extends its lending services to cooperative societies, associations, companies, builders, developers, and contractors, ensuring a diverse clientele while conducting all operations within India.

Aviceda Therapeutics is a late-stage, pre-clinical biotechnology company focused on developing innovative treatments for glyco-immune diseases. By leveraging glycobiology and a proprietary cell-based high-throughput screening platform, the company aims to create next-generation immunomodulators that target the innate immune system and address chronic non-resolving inflammation. Aviceda's product pipeline includes candidates for a variety of conditions, such as eye diseases, fibrosis, neurology, and oncology. Key products under development include AVD-104, AVD-302, and AVD-401 for dry eye, diabetic retinopathy, and retinoblastoma, as well as AVD-601, AVD-701, and AVD-801 targeting oncology, neurology, and fibrosis. Through its advanced technologies and biological insights, Aviceda seeks to provide breakthrough glycol-therapeutics that improve patient outcomes.

35Pharma is a biopharmaceutical company focused on designing and developing innovative biologics to address diseases with significant unmet medical needs, particularly pulmonary hypertension and musculoskeletal disorders. The company leverages its expertise in protein engineering and a comprehensive understanding of transforming growth factor (TGF)-beta structure-function relationships to create highly effective ligand traps. These advancements aim to facilitate the development of targeted biologics for treating patients suffering from cardio-pulmonary and metabolic diseases.

Beta Bionics is a biotechnology company focused on developing an integrated bionic pancreas system known as the iLet. This innovative device aims to alleviate the challenges and costs associated with diabetes care by providing a dual-chamber infusion pump that delivers insulin and glucagon with precision. The iLet autonomously calculates and administers the necessary doses, enabling patients to effectively manage their blood sugar levels. The system has received breakthrough designation for all its configurations, including insulin-only, glucagon-only, and bihormonal options, and is compatible with Zealand Pharma’s dasiglucagon, a glucagon analogue known for its stability in a ready-to-use aqueous solution. Through this technology, Beta Bionics seeks to improve the quality of life for individuals living with diabetes.

Inquis Medical is focused on developing innovative thrombectomy technology aimed at enhancing the management of venous thromboembolic diseases. The company's medical devices are designed to address unmet clinical needs while improving the standard of care in this area. Inquis Medical's key offering is an efficient single-pass thrombectomy system that minimizes blood loss, contributing to better patient outcomes. Through its advanced technology, Inquis Medical seeks to provide solutions that have a lasting impact on the treatment of thromboembolic conditions.

Evommune, Inc. is a biotechnology company based in Los Altos, California, that focuses on developing and manufacturing tissue-based medicines aimed at treating inflammatory diseases. Founded in 2020, the company employs a proprietary tissue-based platform to accelerate the discovery of novel therapies, with a particular emphasis on immunology and dermatology. Evommune's approach seeks not only to alleviate the symptoms of inflammatory disorders but also to halt disease progression, thereby improving the quality of life for patients. Its pipeline includes initiatives targeting prevalent inflammatory conditions, with a commitment to advancing patient care by creating best-in-class treatment options. Through innovative strategies, Evommune aims to drive meaningful advancements in the field of inflammatory disease management.

Elektrofi is a preclinical-stage company based in Boston, Massachusetts, focused on advancing drug delivery methods to enhance patient experiences. Established in 2016, the company has developed a formulation system capable of processing a diverse array of therapeutic molecules, including large and complex proteins such as monoclonal antibodies, bispecifics, and fusion proteins. Its innovative technology aims to improve subcutaneous administration, allowing drug manufacturers to create breakthrough therapies that empower patients with more control over how they receive essential medications.

Pathalys Pharma is a clinical biopharmaceutical company focused on developing innovative therapeutics for late-stage chronic kidney disease. The company primarily aims to address the unmet medical need associated with secondary hyperparathyroidism (SHPT), a condition characterized by the overactivity of the parathyroid glands due to external diseases. Pathalys is developing upacicalcet, a novel calcimimetic designed to improve SHPT treatment in patients undergoing hemodialysis. Upacicalcet works by mimicking the action of calcium on tissues, activating the calcium-sensing receptor found in various human organs. This approach has the potential to enhance patient care for those suffering from end-stage chronic kidney disease.

Human Interest is a 401(k) provider that simplifies retirement savings for small and medium-sized businesses. Founded in 2015 in San Francisco by Paul Sawaya and Roger Lee, the company developed an end-to-end technology platform that addresses administrative and compliance challenges associated with retirement plans. This platform automatically creates employee accounts and syncs deductions with payroll providers, ensuring a streamlined process. In addition to facilitating employee retirement accounts, Human Interest offers personalized investment advice, enabling businesses to provide their employees with effective financial security solutions. The company has successfully assisted thousands of businesses across the United States in establishing accessible and affordable retirement plans.

Lycia Therapeutics is a biotechnology firm focused on discovering and developing first-in-class therapies. The company utilizes its innovative lysosomal targeting chimeras (LYTACs) platform to create therapeutics that target and degrade extracellular and membrane-bound proteins associated with challenging diseases, including cancer and autoimmune disorders. By addressing these difficult-to-treat conditions, Lycia Therapeutics aims to provide medical practitioners with effective treatment options to improve patient outcomes.

Attovia Therapeutics is a biotherapeutics pipeline developer focused on immune-mediated illness and oncology. The company uses the nanobody platform to create tiny format binders with low picomolar affinity, increased selectivity, quicker internalization, and rapid tissue penetration, thereby assisting cancer patients' treatment.

MindMed provides psychedelic-inspired medicines and therapies for substance abuse disorders and other mental illnesses. The company is assembling a compelling drug development pipeline of innovative treatments based on psychedelic substances including Psilocybin, LSD, MDMA, DMT, and an Ibogaine derivative, 18-MC.

FogPharma is a biotechnology company focused on developing innovative cancer therapies through its unique cell-penetrating mini proteins (CPMPs). Founded by Greg Verdine, the company aims to address cancer-causing proteins that are typically inaccessible to traditional treatments. By collaborating with leading experts in cancer biology and therapy, FogPharma is creating a new class of medicines designed to neutralize these challenging targets. The company is supported by a diverse group of private and institutional investors, which enables it to pursue its mission of delivering transformative cancer treatments. FogPharma is dedicated to improving the lives of patients and their families, striving to extend both life expectancy and quality of life.

enGene, Inc. is a biotechnology company specializing in mucosal immunotherapy platforms aimed at treating inflammatory bowel disease and diabetes. The company has developed a non-integrating biopolymer-based nucleotide delivery technology that enables localized delivery of immune-modulating proteins to mucosal tissues, including the gastrointestinal tract, lung, and bladder. This innovative approach allows for the treatment of various immune disorders and supports systemic release of proteins from the gut to address conditions such as diabetes, anemia, and hemophilia. Founded in 1999 and based in Vancouver, Canada, enGene has formed a strategic alliance with Takeda Pharmaceutical Company Ltd. The company's platform facilitates the induction or suppression of protein expression levels, which can help regenerate physiologic, meal-regulated insulin secretion for diabetes patients.

Areteia Therapeutics is a biotechnology company focused on improving the management of eosinophilic asthma through an innovative oral drug treatment. The company, which emerged from Knopp, aims to provide patients with a novel therapeutic option that inhibits the maturation of eosinophils—cells that can cause airway damage in asthma patients. Its drug candidate has demonstrated promising results in a phase 2 clinical trial, which showed a reduction in blood eosinophil counts, indicating enhanced lung function. This approach seeks to empower patients by offering a potentially effective and accessible treatment for a severe form of asthma, thereby improving their quality of life and disease management.

OnCusp Therapeutics is a biopharmaceutical company focused on developing innovative oncology therapies aimed at improving treatments for cancer patients worldwide. Founded by Bing Yuan, Eric Slosberg, and Andy Fu, the company is dedicated to translating cutting-edge research into clinical applications. It specializes in advancing preclinical drug candidates to the clinical proof-of-concept stage, enabling a swift transition into global early clinical development. By prioritizing this process, OnCusp Therapeutics aims to accelerate the innovation of oncology medications, ultimately providing critical support and hope to those affected by cancer.

Parse Biosciences is a biotechnology company specializing in single-cell analysis and sequencing solutions. Founded in 2018 and based in Seattle, Washington, the company focuses on developing innovative technologies that simplify the sequencing process for researchers. By employing combinatorial cDNA barcoding directly within cells, Parse Biosciences eliminates the necessity for complex and costly microfluidic instruments. This technology allows for the fixing, freezing, and storage of samples, enabling researchers to conduct experiments with samples collected on different dates in a single run. This capability enhances sample handling and minimizes errors, ultimately improving the accuracy of results. The company aims to increase gene detection in individual cells while addressing common challenges associated with single-cell sequencing, thereby advancing research in various scientific fields.

SAB Biotherapeutics, Inc. is a clinical-stage biopharmaceutical development company based in Sioux Falls, South Dakota, with an additional office in Cambridge, Massachusetts. Founded in 2014, the company focuses on developing immunotherapies for various human diseases using its proprietary DiversitAb platform. This innovative platform enables the rapid production of fully targeted human polyclonal antibodies from genetically engineered transchromosomic cattle, eliminating the need for human plasma or serum. SAB Biotherapeutics' product pipeline includes SAB-142 for Type 1 diabetes, SAB-176 for seasonal influenza, and SAB-301 for Middle East Respiratory Syndrome Coronavirus (MERS-CoV). The company's approach aims to address public health challenges, rare diseases, and pandemic threats through advanced antibody science.

BlueWhale Bio is a spinout from the University of Pennsylvania focused on advancing cell-based therapies through innovative manufacturing techniques. The company develops cell drugs aimed at addressing challenges in gene therapy production, specifically to enhance the effectiveness of cancer treatment. By streamlining the manufacturing process, BlueWhale Bio seeks to facilitate the development of effective cancer treatment plans for patients, ultimately improving outcomes in the field of cell therapy.

Beta Bionics is a biotechnology company focused on developing an integrated bionic pancreas system known as the iLet. This innovative device aims to alleviate the challenges and costs associated with diabetes care by providing a dual-chamber infusion pump that delivers insulin and glucagon with precision. The iLet autonomously calculates and administers the necessary doses, enabling patients to effectively manage their blood sugar levels. The system has received breakthrough designation for all its configurations, including insulin-only, glucagon-only, and bihormonal options, and is compatible with Zealand Pharma’s dasiglucagon, a glucagon analogue known for its stability in a ready-to-use aqueous solution. Through this technology, Beta Bionics seeks to improve the quality of life for individuals living with diabetes.

AN2 Therapeutics, Inc. is a biopharmaceutical company based in Menlo Park, California, founded in 2017. The company is dedicated to the research, development, and commercialization of innovative medicines aimed at addressing infectious diseases. AN2 Therapeutics is focused on developing epetraborole, a once-daily oral treatment for patients suffering from chronic non-tuberculous mycobacterial lung disease, which represents a significant unmet medical need. Additionally, the company has established a strategic partnership with Brii Biosciences to enhance its development efforts.

ADARx Pharmaceuticals, Inc. is a clinical-stage biotechnology company based in San Diego, California, focused on the research and development of RNA editing therapeutics. Founded in 2019, the company specializes in the precise targeting and correction of single point mutations on mRNA transcripts using a proprietary platform that leverages endogenous enzymes known as adenosine deaminase acting on RNA (ADAR). This innovative approach aims to restore the production of functional proteins, addressing genetic mutations that lead to various diseases. ADARx Pharmaceuticals is developing a diverse pipeline of ribonucleic acid targeting therapeutics aimed at treating conditions across multiple therapeutic areas, including genetic disorders, cardiometabolic diseases, complement-mediated diseases, and central nervous system disorders.

InspireMD, Inc. is a medical device company headquartered in Tel Aviv, Israel, specializing in the development and commercialization of its proprietary MicroNet stent platform technology aimed at treating vascular and coronary diseases. The company offers the CGuard carotid embolic prevention system, designed for carotid artery applications, and the MGuard Prime embolic protection system, which is used in patients with acute coronary syndromes, including acute myocardial infarction and saphenous vein graft interventions. InspireMD is also working on the NGuard, a neurovascular flow diverter intended to redirect blood flow from cerebral aneurysms. The company primarily generates revenue through the sale of its products via local distributors in various regions, including Europe, Latin America, the Middle East, and Asia.

Prognos Health is a health tech company focused on healthcare analytics, offering a platform called prognosFACTOR. This innovative platform can quickly query billions of lab and health records from over 325 million de-identified patients, providing answers to clinically relevant healthcare questions in a fraction of the time traditionally required. Prognos Health allows clients to access HIPAA-compliant, patient-centric healthcare data through the Prognos Marketplace, facilitating a range of applications such as cohort design, patient journey studies, and health outcomes analysis. The company's clientele includes 25 of the top 30 pharmaceutical manufacturers and three of the top five health payers, highlighting its significant role in empowering precise decision-making throughout the healthcare landscape.

Thunes is a global B2B payment infrastructure platform established in 2016, specializing in cross-border payment solutions. It facilitates seamless fund transfers between various payment systems, catering to a diverse range of clients, including major players in the gig economy and fintech sectors. The platform enables businesses and consumers to send and receive payments in 80 currencies across 132 countries, supporting 300 payment methods. Thunes offers a suite of services including remittance processing, mass payouts, virtual accounts, and payment collection, utilizing application programming interfaces (APIs) to enhance accessibility and reduce transaction costs. In April 2022, the company expanded its capabilities by acquiring a controlling stake in Tookitaki, a compliance platform that strengthens its anti-money laundering and fraud prevention measures. Headquartered in Singapore, Thunes operates regional offices in key global cities such as London, Paris, and Dubai, positioning itself as a vital player in the international payment landscape.

Karyopharm Therapeutics Inc., a pharmaceutical company based in Newton, Massachusetts, specializes in the discovery, development, and commercialization of drugs targeting nuclear transport and related pathways for cancer treatment. Its lead product, XPOVIO (selinexor), is an approved therapy for multiple myeloma, both as a standalone treatment and in combination with other drugs. The company's pipeline includes several clinical-stage compounds, such as BOSTON, STORM, STOMP, and SADAL, which are being evaluated in various blood cancers. Additionally, Karyopharm has collaborations with other organizations for COVID-19 and neurological disease research.

TRM Labs Inc. is a blockchain intelligence company that provides a platform focused on token relationship management, utilizing machine learning to assist clients in managing customer relationships and detecting suspicious activities. The platform offers solutions for on-chain anti-money laundering (AML) compliance, including customer due diligence, transaction monitoring, and relationship management specifically tailored for digital asset firms. Additionally, TRM Labs develops enterprise applications and tools that enable organizations to launch blockchain-based products aimed at identifying fraudulent activities such as money laundering and market manipulation. Founded in 2017 and headquartered in San Francisco, California, the company serves a diverse clientele, including financial institutions, cryptocurrency businesses, and government agencies, and has established partnerships with notable organizations such as PayPal, Visa, and federal agencies. TRM Labs is committed to enhancing the safety of the financial ecosystem through advanced data engineering and threat intelligence, backed by a team of experts with extensive experience in law enforcement and technology.

VectivBio AG is a clinical-stage biotechnology company based in Basel, Switzerland, founded in 2019 as a spinout from Therachon. The company specializes in the discovery, development, and commercialization of innovative treatments for severe rare diseases, particularly those with significant unmet medical needs. Its lead product candidate, Apraglutide, is a synthetic GLP-2 analog designed to enhance the intestine’s ability to absorb fluids and nutrients, thereby reducing the reliance on parenteral support in patients with short bowel syndrome. VectivBio is dedicated to developing best-in-disease therapies that aim to meaningfully improve the lives of patients and their families, providing more than just incremental advancements over existing standard-of-care options.

Acelyrin is a late-stage clinical biopharmaceutical company dedicated to advancing new treatment options for patients. The company specializes in identifying, acquiring, and accelerating the development and commercialization of promising drug candidates. By leveraging its expertise, Acelyrin aims to rapidly bring transformative medicines to market, ultimately improving patient outcomes and quality of life.

Neurolens is a company that specializes in prescription lenses designed to alleviate discomfort caused by eye misalignment. Founded in 2012 and based in Costa Mesa, California, Neurolens incorporates a contoured prism into its lenses to improve eye alignment, which can help relieve headaches, neck and shoulder pain, and eyestrain. The company has developed a vision measurement device that utilizes an eye-tracking system capable of detecting even minor misalignments, measured in prism diopters. This innovative approach aims to address the chronic discomfort many individuals experience due to prolonged use of digital devices, reading, or engaging in detailed work.

21Shares AG, established in 2018 and headquartered in Zug, Switzerland, specializes in developing and managing crypto exchange-traded products. The company offers a range of index-based products, including the 21Shares Crypto Basket Index (HODL5), which provides diversified exposure to the top five cryptocurrencies, listed on the Swiss Stock Exchange. 21Shares aims to make cryptocurrency investing accessible, secure, and regulated, enabling investors to buy, sell, and short cryptocurrencies through existing bank and brokerage accounts. The company's issuance platform, Onyx, is used for issuing and operating cryptocurrency ETPs worldwide.

21.co is a cryptocurrency company providing access to crypto through simple and easy-to-use products. 21.co is the parent company of 21Shares, the world’s largest issuer of cryptocurrency exchange-traded products (ETPs) – which is powered by Onyx, a proprietary technology platform used to issue and operate cryptocurrency ETPs for 21Shares and third parties – in addition to Amun, a token provider focused on making the Defi world more accessible. The company was founded in 2018 by Hany Rashwan and Ophelia Snyder. 21.co is registered in Zug, Switzerland with offices in Zurich and New York.

Elektrofi is a preclinical-stage company based in Boston, Massachusetts, focused on advancing drug delivery methods to enhance patient experiences. Established in 2016, the company has developed a formulation system capable of processing a diverse array of therapeutic molecules, including large and complex proteins such as monoclonal antibodies, bispecifics, and fusion proteins. Its innovative technology aims to improve subcutaneous administration, allowing drug manufacturers to create breakthrough therapies that empower patients with more control over how they receive essential medications.

Turtlemint is an online insurance platform based in Mumbai, Maharashtra, India, that simplifies the process of buying and managing insurance policies. Founded in 2015, the company aims to make insurance accessible and understandable by demystifying complex jargon and providing user-friendly tools. Turtlemint offers a range of insurance products, including car, bike, health, and term life insurance, allowing customers to search, compare, and purchase policies entirely online with just a few clicks. The platform leverages proprietary algorithms and data analytics to provide personalized recommendations, while also offering a network of offline facilitators to assist with the purchase and claims process. This comprehensive approach enables clients to select the right insurance schemes tailored to their needs.

Circle is a financial technology firm established in 2013 by Jeremy Allaire and Sean Neville, headquartered in Boston, with additional offices in New York, San Francisco, Dublin, London, and Hong Kong. The company leverages blockchain technology to facilitate payments and e-commerce through stablecoins and its Circle Pay platform, streamlining the process of sending money. Circle offers a range of services, including Circle Invest, which allows users to buy and sell cryptocurrency assets, and Circle Trade, which provides over-the-counter trading services with access to one of the largest global liquidity pools for digital asset trading, averaging $2 billion in monthly volume. Backed by prominent investors such as Goldman Sachs and Accel Partners, Circle positions itself as a key player in the global internet finance sector, focused on integrating crypto assets into mainstream financial applications.

Parse Biosciences is a biotechnology company specializing in single-cell analysis and sequencing solutions. Founded in 2018 and based in Seattle, Washington, the company focuses on developing innovative technologies that simplify the sequencing process for researchers. By employing combinatorial cDNA barcoding directly within cells, Parse Biosciences eliminates the necessity for complex and costly microfluidic instruments. This technology allows for the fixing, freezing, and storage of samples, enabling researchers to conduct experiments with samples collected on different dates in a single run. This capability enhances sample handling and minimizes errors, ultimately improving the accuracy of results. The company aims to increase gene detection in individual cells while addressing common challenges associated with single-cell sequencing, thereby advancing research in various scientific fields.

Metagenomi, Inc. is a biotechnology company focused on developing gene editing systems aimed at treating genetic diseases. Founded in 2016 and based in Emeryville, California, Metagenomi utilizes metagenomics and machine learning to uncover novel genome editing technologies derived from previously uncharacterized organisms. The company's innovative discovery platform enables the creation of highly efficient and specific gene editing tools, including programmable nucleases, base editors, and advanced integration systems such as prime editing and CRISPR-associated transposases. By harnessing these naturally evolved systems, Metagenomi seeks to address a wide range of genetic mutations that traditional genome engineering approaches have struggled to target, with the ultimate goal of providing transformative therapies for patients globally.

Lukka, Inc. is a blockchain-native technology company based in New York that specializes in providing middle and back office solutions for the crypto-asset ecosystem. Founded in 2014 and rebranded from Libra Services, Inc. in 2019, Lukka focuses on managing and processing complex blockchain and cryptocurrency data to enhance accessibility and utility for businesses. Its offerings include LukkaTax, which simplifies tax calculations and compliance for cryptocurrency transactions, and LukkaCrypto Office, a back-office solution for managing crypto assets that features pricing, valuation, and reporting capabilities. Additionally, Lukka Reference Data ensures the consistency and accuracy of crypto asset data for enterprise applications. By automating and optimizing accounting, audit, and tax processes, Lukka delivers real-time visibility into crypto transaction activity, catering to the reporting and compliance needs of funds, fund administrators, exchanges, and enterprises.

Accelerant Holdings Ltd. is a managing general agent (MGA) based in London, United Kingdom, founded in 2018. The company specializes in providing wholesale insurance underwriting services primarily for small and medium-sized enterprises (SMEs). As an insurtech, Accelerant leverages advanced data analytics and technology to enhance its risk exchange platform, enabling underwriters to access superior insights and capacity commitments. The firm's specialty portfolio is well-diversified, minimizing exposure to catastrophe and systemic risks. Additionally, Accelerant has established a carefully selected network of underwriting teams to ensure high-quality service delivery, earning it an excellent AM Best A- rating.

Tipalti, Inc., established in 2010, specializes in accounts payable automation and global mass payments. Headquartered in San Mateo, California, with an additional office in Israel, the company offers a comprehensive software solution that streamlines and automates the process of paying suppliers, partners, and publishers worldwide. Tipalti's platform covers all aspects of the payables workflow, including supplier onboarding, invoice processing, global funds disbursement, tax compliance, and payment reconciliation. By utilizing Tipalti, businesses can significantly reduce their supplier payment workload, strengthen financial controls, ensure regulatory compliance, and improve partner payment experiences, enabling them to focus on strategic growth.

TRM Labs Inc. is a blockchain intelligence company that provides a platform focused on token relationship management, utilizing machine learning to assist clients in managing customer relationships and detecting suspicious activities. The platform offers solutions for on-chain anti-money laundering (AML) compliance, including customer due diligence, transaction monitoring, and relationship management specifically tailored for digital asset firms. Additionally, TRM Labs develops enterprise applications and tools that enable organizations to launch blockchain-based products aimed at identifying fraudulent activities such as money laundering and market manipulation. Founded in 2017 and headquartered in San Francisco, California, the company serves a diverse clientele, including financial institutions, cryptocurrency businesses, and government agencies, and has established partnerships with notable organizations such as PayPal, Visa, and federal agencies. TRM Labs is committed to enhancing the safety of the financial ecosystem through advanced data engineering and threat intelligence, backed by a team of experts with extensive experience in law enforcement and technology.

ConsenSys, established in 2015 by Ethereum co-founder Joseph Lubin, is a leading Ethereum software company focused on Web3. It offers a suite of products, including Infura, Quorum, Truffle, Codefi, MetaMask, and Diligence, which serve millions of users and support billions of blockchain-based queries. ConsenSys enables developers and enterprises worldwide to build next-generation applications and access the decentralized web, fostering business adoption and growth of the Ethereum ecosystem. Additionally, ConsenSys Academy, its educational arm, bridges the Ethereum knowledge gap globally for ecosystem development.

Acelyrin is a late-stage clinical biopharmaceutical company dedicated to advancing new treatment options for patients. The company specializes in identifying, acquiring, and accelerating the development and commercialization of promising drug candidates. By leveraging its expertise, Acelyrin aims to rapidly bring transformative medicines to market, ultimately improving patient outcomes and quality of life.

Acrivon Therapeutics is a clinical-stage biopharmaceutical company focused on precision oncology, developing therapeutics that target challenging cancer types without straightforward single-gene mutations. The company employs a proteomics-based platform to identify patients whose tumors are likely to respond to specific treatments. Acrivon's pipeline includes ACR-368, also known as prexasertib, which is currently in Phase 2 trials, alongside preclinical programs aimed at key components of DNA damage response and cell cycle regulation, such as the WEE1 and PKMYT1 proteins. Acrivon seeks to expedite the development of both in-licensed clinical-stage assets and its internally developed programs through accelerated registration trials, aiming to enhance treatment success in oncology.

Vayana Network is a financing network that facilitates electronic trade transactions between businesses and their trade partners. It enables companies to efficiently manage their receivables and payables by connecting them with banks and financial institutions for financing options. Through its online lending platform, Vayana Network provides working capital finance specifically designed for small and medium enterprises, allowing them to access short-term business loans to support growth. The company also offers a Commercial Card solution in collaboration with MasterCard and various banks, enhancing payable financing options for its clients. By streamlining the trade financing process, Vayana Network aims to empower businesses in managing their financial operations more effectively.

CRED is a members-only credit card management and bill payments platform that rewards users every time they pay their credit card bills. The fintech startup operates an app that rewards customers for paying their credit card bills on time and gives them access to a range of additional services such as credit and a premium catalog of products from high-end brands. Customers are offered a range of features which include the ability to better track spending across various credit cards, and get reminders. Cred is backed by investors such as Falcon Edge Capital, Coatue Management, Insight Partners, DST Global, RTP Global, Tiger Global, Greenoaks Capital, Dragoneer Investment Group, and Sofina. It was established in Bengaluru, Karnataka by Kunal Shah in 2017.

Varo Money, Inc. is a digital bank based in San Francisco, California, that offers a range of online banking products and services, including bank and savings accounts, checking accounts, and overdraft protection. Established in 2015 and known for being the only U.S. consumer fintech with a national bank charter, Varo aims to serve as a comprehensive banking partner for millions of Americans, especially those seeking better financial solutions. The company combines fintech innovation with the security of a chartered bank, providing tools and insights to enhance financial resilience for its customers. Varo's platform also includes features such as spending analysis, real-time budgeting, cash flow forecasts, direct deposits, and online bill payments, all designed to empower users to make informed financial decisions and improve their overall financial well-being.

Inbrace is a medical device company focused on innovative orthodontic solutions. Its flagship product, INBRACE, is a discreet alignment system that is placed behind the teeth, utilizing patented self-guiding technology to apply continuous forces for gentle correction of dental alignment. This approach significantly reduces pain and minimizes the number of required visits to the orthodontist, addressing common patient concerns and enhancing satisfaction. INBRACE is FDA registered and aims to expand access to orthodontic treatment, thereby driving practice growth for dental professionals. The company's platform incorporates digital treatment planning, computer modeling, and direct digital manufacturing, allowing for customized solutions that maintain high standards of care across various orthodontic cases.

Asher Biotherapeutics, Inc. is a biotechnology company based in South San Francisco, California, founded in 2019. The company specializes in the development of immunotherapy drugs aimed at effectively treating cancer. Its innovative therapies are designed to enhance the immune system's ability to target and eliminate cancer cells while minimizing side effects. This focus allows healthcare providers to deliver effective treatments to patients in a shorter timeframe, aiming to improve overall outcomes in cancer care.

Neurogastrx, Inc. is a venture-stage biopharmaceutical company focused on developing innovative therapies for gastrointestinal disorders. Established in 2017 and located in Campbell, California, the company aims to address the unmet medical needs associated with functional and motility disorders of the gastrointestinal tract. One of its key products, NG101, is designed to enhance gastric motility while also possessing antiemetic properties. Neurogastrx's specialty therapies target the enteric nervous system, addressing issues related to gut contractions, sensation, and the brain-gut axis, ultimately striving to alleviate the burden of these disorders on patients and the healthcare system.

Amylyx Pharmaceuticals develops innovative therapies for Amyotrophic Lateral Sclerosis (ALS) and other neurodegenerative diseases. The company's primary product, AMX0035, is an investigational therapy that combines two active compounds, sodium phenylbutyrate and Taurursodiol. This fixed-dose formulation aims to address mitochondrial energy crises and the accumulation of toxic proteins in the endoplasmic reticulum, which contribute to neurological decline. In addition to ALS, Amylyx's research pipeline includes potential treatments for Wolfram syndrome and Alzheimer's disease. Founded in 2013 and based in Cambridge, Massachusetts, Amylyx Pharmaceuticals is dedicated to advancing solutions for serious brain disorders.

Circle is a financial technology firm established in 2013 by Jeremy Allaire and Sean Neville, headquartered in Boston, with additional offices in New York, San Francisco, Dublin, London, and Hong Kong. The company leverages blockchain technology to facilitate payments and e-commerce through stablecoins and its Circle Pay platform, streamlining the process of sending money. Circle offers a range of services, including Circle Invest, which allows users to buy and sell cryptocurrency assets, and Circle Trade, which provides over-the-counter trading services with access to one of the largest global liquidity pools for digital asset trading, averaging $2 billion in monthly volume. Backed by prominent investors such as Goldman Sachs and Accel Partners, Circle positions itself as a key player in the global internet finance sector, focused on integrating crypto assets into mainstream financial applications.

Pine Labs is a technology and financial solutions provider focused on enhancing merchant operations and increasing revenue. The company offers a comprehensive platform that facilitates both online and offline transactions, enabling retailers to connect with financial institutions and consumer brands efficiently. Its services include processing easy monthly installment transactions, delivering customer insights for targeted sales, and simplifying payment acceptance. Pine Labs supports over 350,000 POS terminals across 3,700 cities in India and Malaysia, catering to more than 100,000 merchants in diverse sectors such as electronics, food and beverage, fashion, and airlines. The company collaborates with 15 major banks and 7 financial institutions, ensuring a robust ecosystem for retailers to engage and retain customers while minimizing operational complexities and risks.

Forge Biologics, Inc. is a contract development and manufacturing organization based in Columbus, Ohio, focused on developing and manufacturing gene therapies and genetic medicines. The company specializes in viral vector gene therapies aimed at treating genetic diseases, including a novel approach combining adeno-associated virus (AAV) with umbilical cord transplants for infantile Krabbe disease, a severe neurodegenerative condition. Founded in 2019, Forge Biologics partners with scientists, healthcare professionals, and biotech and pharmaceutical companies to facilitate the transition of gene therapy programs from preclinical development to clinical and commercial-scale production. By providing end-to-end capabilities, the company aims to accelerate the availability of transformative medicines for patients suffering from rare genetic disorders.

Exscientia is a biotechnology company that leverages artificial intelligence and machine learning to enhance the discovery and design of novel therapeutic compounds. By integrating human expertise with advanced computational techniques, Exscientia accelerates the development of small-molecule drug candidates, aiming to produce safe and effective treatments for clinical testing. The company's innovative approach seeks to revolutionize the pharmaceutical industry by improving the precision and efficiency of drug discovery, ultimately enhancing patient outcomes.

Flywire is a payments enablement and software company headquartered in Boston, Massachusetts, that specializes in providing secure payment solutions for various industries, including education and healthcare. The company leverages its proprietary global payments network, an advanced payments platform, and industry-specific software to facilitate complex transactions for over 4,000 clients worldwide. Flywire supports a diverse range of payment methods, allowing transactions in more than 140 currencies across 240 countries and territories. Its solutions aim to streamline the process of receiving reconciled domestic and international payments, enhancing cost-effectiveness and efficiency for its clients. The majority of Flywire's revenue is generated from the Americas, reflecting its strong presence in the region.

Century Therapeutics, Inc. is a biotechnology company focused on developing innovative cell therapies derived from induced pluripotent stem cells (iPSCs) to treat hematologic and solid malignancies. Founded in 2018 and headquartered in Philadelphia, Pennsylvania, the company utilizes a specialized platform that integrates gene editing and protein engineering to create allogeneic therapies. This platform allows for the generation of master cell banks of modified immune effector cells, specifically engineered to optimize performance and reduce the risk of rejection by the host immune system. By employing advanced technologies such as CRISPR-mediated gene editing and proprietary chimeric antigen receptors, Century Therapeutics aims to address significant unmet medical needs in cancer and other diseases.

International Airlines Group is one of the world's largest airline groups. Transporting passengers and cargo generates revenue. It has multiple subsidiaries and attempts to combine leading airlines in Ireland, the United Kingdom, and Spain. It allows airlines to expand global presence and keep individual brands. Staff reports operating segments in a manner consistent with resource-allocation decisions, and are listed as four subsidiaries: British Airways, Iberia, Vueling, and Aer Lingus. Each segment is managed as individual operating companies. Revenue is split between the United Kingdom (roughly one third), Spain, the United States, and the rest of the world.

LGI Homes, Inc. is a homebuilder based in The Woodlands, Texas, specializing in the design, construction, and sale of new homes across the United States. Founded in 2003, the company offers a range of residential properties, including entry-level homes, move-up homes, and luxury series homes marketed under the Terrata Homes brand. LGI Homes operates 113 communities across various states, including Texas, Arizona, Florida, and Georgia, among others. The company provides a selection of floor plans and customizable features, such as granite countertops and ceramic tile flooring, catering to diverse customer needs. With a focus on delivering quality homes at competitive prices, LGI Homes serves a wide array of markets through its multiple operating segments.